«Possibilities of a unified approach to the treatment of IgE-associated respiratory diseases. Clinical Experience exchange».

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access


Inflammatory diseases of the upper and lower respiratory airways, such as allergic rhinitis, nasal polyposis, bronchial asthma have common proinflammatory mechanisms, mediated by IgE-dependent cascade of inflammation. Concurrent existence of asthma and allergic rhinitis and/or nasal polyposis increases clinical symptoms severity, disease course aggravation and eventually disease control loss for the patient. Anti-IgE-therapy is pathogenetically justified effective and safe therapeutic option for various patient groups. Today principles of interdisciplinary approach are in practice to target upper and lower respiratory diseases management, which determines the success of biological therapy. ENT, pulmonology and allergy specialists define patient management tactics in close collaboration taking into consideration diseases manifestation. The proven efficacy and safety of оmalizumab makes this drug a universal tool to achieve IgE-associated diseases control and an alternative solution for surgical intervention and therapy with systemic corticosteroids.

Full Text

Restricted Access

About the authors

Olga P. Ukhanova

Stavropol Regional Clinical Hospital

Author for correspondence.
Email: uhanova_1976@mail.ru
ORCID iD: 0000-0002-7247-0621
SPIN-code: 8287-2891

MD, Dr. Sci. (Med.), Professor

Russian Federation, Stavropol

Dmitrii V. Karamishev

Moscow Regional Research Clinical Institute named by M.F. Vladimirskiy

Email: d.v.karamyshev@bk.ru
ORCID iD: 0000-0002-1323-4821
SPIN-code: 9930-2075


Russian Federation, Moscow

Kseniya A. Ryabova

The First Sechenov Moscow State Medical University

Email: acksinja@gmail.com
ORCID iD: 0000-0003-0520-0936
SPIN-code: 9000-6894

MD, Research Associate

Russian Federation, Moscow

Fatimat Hanova

The National Medical Research Center for Otorhinolaryngology of the Federal Medico-Biological Agency of Russia

Email: fmkhanova@yahoo.com
ORCID iD: 0000-0001-9362-9139
SPIN-code: 5320-2821

MD, Cand. Sci. (Med.)

Russian Federation, Moscow


  1. Palomares Ó, Sánchez-Ramón S, Dávila I, et al. dIvergEnt: How IgE axis contributes to the continuum of allergic asthma and anti-ige therapies. Int J Mol Sci. 2017;18(6):1328. doi: 10.3390/ijms18061328
  2. Cheng SL. Immunologic pathophysiology and airway remodeling mechanism in severe asthma: focused on IgE-Mediated pathways. Diagnostics (Basel). 2021;11(1):83. doi: 10.3390/diagnostics11010083
  3. Phillips KM, Hoehle LP, Caradonna DS, et al. Association of severity of chronic rhinosinusitis with degree of comorbid asthma control. Ann Allergy Asthma Immunol. 2016;117(6):651–654. doi: 10.1016/j.anai.2016.09.439
  4. Leynaert B, Neukirch F, Demoly P, et al. Epidemiologic evidence for asthma and rhinitis comorbidity. J Allergy Clin Immunol. 2000;106(5 Suppl):S201–205. doi: 10.1067/mai.2000.110151
  5. Allergic rhinitis: clinical recommendations (Approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation). RAAKI; 2020. (In Russ). Avalable from: https://raaci.ru/education/clinic_recomendations/471.html
  6. Giavina-Bianchi P, Aun MV, Takejima P, et al. United airway disease: current perspectives. J Asthma Allergy. 2016;9:93–100. doi: 10.2147/JAA.S81541
  7. Humbert M, Bousquet J, Bachert C, et al. IgE-Mediated multimorbidities in allergic asthma and the potential for omalizumab therapy. J Allergy Clin Immunol Pract. 2019;7(5):1418–1429. doi: 10.1016/j.jaip.2019.02.030
  8. Okubo K, Okano M, Sato N, et al. Add-on omalizumab for inadequately controlled severe pollinosis despite standard-of-care: a randomized study. J Allergy Clin Immunol Pract. 2020; 8(9):3130-3140.e2. doi: 10.1016/j.jaip.2020.04.068
  9. Gevaert P, Omachi TA, Corren J, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol. 2020;146(3):595–605. doi: 10.1016/j.jaci.2020.05.032
  10. Tsabouri S, Tseretopoulou X, Priftis K, Ntzani EE. Omalizumab for the treatment of inadequately controlled allergic rhinitis: a systematic review and meta-analysis of randomized clinical trials. J Allergy Clin Immunol Pract. 2014;2(3):332–40.e1. doi: 10.1016/j.jaip.2014.02.001
  11. Yu C, Wang K, Cui X, et al. Clinical efficacy and safety of omalizumab in the treatment of allergic rhinitis: a systematic review and meta-analysis of randomized clinical trials. Am J Rhinol Allergy. 2020;34(2):196–208. doi: 10.1177/1945892419884774
  12. Ukhanova OP, Dzhabarova AA, Sivun IV, Buryndina EI. Prospects of gene-engineering therapy of seasonal allergic rhinitis of severe course. Bulletin of Modern Clinical Medicine. 2018;11(2):36–40. (In Russ). doi: 10.20969/VSKM.2018.11(2).36-40.

Supplementary files

Supplementary Files
1. Fig. 1. ISAC ImmunoCap allergy chip, patient D. 40 years old results, dated 23.04.2019.

Download (365KB)
2. Fig. 2. The dynamics of rhinosinusitis with nasal polyps according to paranasal sinuses CT scan (September 2018 – September 2020): a ― image after endoscopic polysinusotomy was performed in September 2018 (polypous mass in maxillary, sphenoidal sinuses, in ethmoid sinuses); b ― image 24 month from the start of anti-IgE therapy (only parietal mucosal thickening in maxillary, sphenoidal sinuses, in ethmoid sinuses with airness restoration in paranasal sinuses).

Download (193KB)

Copyright © Pharmarus Print Media, 2021

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies